Informa helps businesses and professionals in hundreds of ways.

Our international portfolio of live events, world-leading research publications, and innovative digital services provide specialists with the knowledge and connections they need to thrive.

Registration is now live! Get your complimentary pass today.

Child-Resistant vs. Senior-Friendly: Balancing Safety and Accessibility in Asian Markets

14th August 2026

The Asia-Pacific is facing a demographic shift that is set to have profound consequences on how its pharma industry prioritises its operations going forward. The region is home to approximately 60% of the world's population aged 65+, [1] a figure which is only set to increase in the coming years. Meanwhile, birth rates in the Asia-Pacific remain high, creating a dual need for healthcare services for later-life patients and paediatric treatments.

What’s more, the packaging requirements for medication geared towards these two demographics are diametrically opposed. Paediatric medicines need to be stored in child-resistant packaging to prevent easy access, while drugs for older patients needs to be senior-friendly, catering to experiencing age-related conditions including arthritis or reduced manual dexterity. Medications which are designed for both groups must therefore be packaged securely but accessibly, giving pharma packaging manufacturers a near-impossible balance to strike. For packaging to be truly patient-centric, it also needs to ensure that its end users can access it easily and safely, without providing a barrier which keeps them from taking it as often as required. According to World Health Organisation estimates, difficult-to-open packaging is a significant factor in the 50% medication non-adherence rate [2] in the management of chronic disease in developed countries.

Beyond navigating this issue, pharma organisations operating in the Asia-Pacific also have to meet multiple distinct regulatory requirements across different parts of the region. For example, while markets like Australia and Japan have implemented comprehensive requirements around child-resistant packaging in alignment with international standards, India and several Southeast Asian countries are more reliant on voluntary practices. This fragmented regulatory landscape creates challenges for pharmaceutical companies seeking to standardise their packaging solutions across regional markets. All of this begs a simple question – what can be done to keep medication accessible to all, while still catering to two very different sets of end-user needs?

Ageing and Accessibility: A Demographic Challenge

The shift in the demographic makeup of the Asia-Pacific is one of the most significant of the twenty-first century, with profound implications for healthcare systems [3] and pharmaceutical markets. Japan not only leads the region’s ageing trends, but the world’s, with approximately 29% of its population aged 65 and up as of 2024; comparatively, in South Korea, Singapore, Thailand and China, populations are ageing at a rate which will in elderly populations of over 20% within the next decade. This creates expanding markets for chronic disease medications which disproportionately affect elderly populations, simultaneously creating imperatives for packaging designs to accommodate older adults’ physical capabilities and limitations.

Limitations such as reduced manual dexterity, visual impairment and cognitive decline all need to be factored into the packaging design of any medication geared towards an ageing population. However, these physical issues also make traditional child-resistant packaging like push-and-turn-closure bottles or blister packs more challenging to use. Research examining the opening capabilities of children and elderly adults has documented substantial overlap in their physical capabilities, with some elderly adults possessing grip strength and manual dexterity comparable to or less than children aged between 4 and 5.

The implications of inaccessible packaging on medication adherence are substantial, encouraging elderly patients to skip doses if they are unable to open containers, or require external assistance in doing so which may not always be available. At the same time, these packaging solutions will need to be child-resistant and prevent cross-contamination and environmental degradation. This gives pharmaceutical companies a serious imperative to devise and implement packaging designs that are truly accessible for all.

Regulatory Frameworks Governing Child-Resistant Packaging in the Asia-Pacific

ISO standards have created consistent criteria to define packaging safety across international markets, which serves as the basis for many regulations within the Asia-Pacific. For example, the tests which established the ISO 8317 [4] standard required that at least 85% of children aged between 42–51 months cannot open packaging within a five-minute test period, while at least 90% of adults aged 50–70 years could open and properly reclose the same packaging. This dual performance requirement explicitly recognises the need to balance child resistance with adult accessibility, but Asia-Pacific markets may need to conduct further safety tests to ensure that pharma packaging can address the capabilities of its rapidly growing oldest population.

Japan's Pharmaceutical and Medical Devices Agency has implemented child-resistant packaging requirements for certain categories of high-risk medication, with regulations more aligned with the country’s specific physical and cultural preferences. The country’s regulations emphasise the need for clear labelling which provides unambiguous instructions for proper package opening and reclosing procedures, spotlighting the importance of both mechanical design and user understanding for product safety. China, by contrast, has not outlined comprehensive mandatory requirements around child-proofing its packaging, but the country’s National Medical Products Administration has issued guidance for pharma companies on a more voluntary basis.

Meanwhile, with its sprawling pharmaceutical regulatory framework, India has traditionally overlooked accessibility and child-resistance in its pharma packaging. However, rising awareness of the risk of paediatric poisoning, coupled with a drive for better alignment with international regulatory bodies, has led industry conversations in an encouraging direction. However, India’s pharma distribution network is fragmented, with pharmacists often dispensing medication separate from its original packaging, which creates a challenging environment for authorities to put measures of this nature into place.

Balancing Safety and Accessibility for Innovative Design

Pharmaceutical packaging engineers have developed a range of design approaches in an effort to reconcile the twin needs of child-resistance and senior accessibility. These are more reliant on cognitive differences between children and adults, rather than their physical capabilities, such as written instructions or visual cues, which creates a barrier to entry for children, while not excluding older users. One such example of cognitive design is the reverse-logic closure system, which requires users to push down and turn simultaneously to open a container; these closures can be designed with relatively low torque requirements, to accommodate users with reduced grip strength, while continuing to maintain effective child resistance through its relative operational complexity. As long as instructions are presented clearly, these reverse-logic designs could be a possible step towards a safer and more inclusive future for pharma packaging.

Peel-push blister packaging, which incorporates perforated backing materials to peel away rather than pushing through a foil seal, has also become a viable alternative to traditional push-through blister formats. This addresses concerns around require finger strength and precision which is not always viable for older patients, but retaining the same unit-dose integrity and tamper evidence as its more familiar version. Peel-push designs do, however, require their materials to be carefully selected, to prevent the top layer from being too easy to peel.

Dual-access packaging systems incorporate both child-resistant and easy-open features, letting users choose the appropriate access methods for their household circumstances. Specifically, this packaging will incorporate a child-resistant closure as its primary access mechanism, with an alternative easy-open feature for situations where there is no chance a child would be able to access the medication. Dual-access systems have been accepted as a packaging system by some regulatory bodies, though concerns remain about the easy-open feature being too accessible to be considered child-resistant.

Get involved

Whether you're exhibiting or attending, Pharmapack Asia is your gateway to forging meaningful and lasting connections in the pharmaceutical industry.

Attend

Discover innovative pharma packaging and drug delivery solutions for high value and complex drugs.

Exhibit

Ready to showcase innovation? Secure a stand at Southeast Asia's premier packaging event.

The Human Factor: Testing Methodologies for Dual-Performance Packaging

Validating packaging designs that simultaneously meet child resistance and senior accessibility needs requires comprehensive testing protocols. As discussed above, dual-performance packaging addresses the needs of both groups simultaneously, but testing the efficacy of any newly-designed packaging requires careful protocol development around  a multitude of factors. These include sample size, participant selection criteria, performance metrics and success criteria, all of which must balance accessibility objectives with child-resistance requirements.

Usability testing methodologies for pharmaceutical packaging have evolved to incorporate human factor engineering principles, which examine whether users can successfully open packages with a focus on real-world pain points: time taken, the number of attempts, user frustration levels and the potential for incorrect operation that could compromise child resistance or product integrity. These comprehensive assessments offer insights into where designs can be optimised, identifying specific features that could create barriers in order to enable a more iterative approach to design refinement. The application of human factor methodologies to packaging design represents an emerging best practice, and suggesting a significant training opportunity for Asia-Pacific companies operating in this area.

Validating packaging performance in real-world conditions continues to be an industry challenge, due to the fundamental difference between home environments and controlled laboratory settings. The condition of the packaging after repeated attempts at opening and reclosing, a user’s familiarity with packaging formats and even environmental conditions affecting material properties can all influence packaging performance in ways that standardised testing protocols are unable to capture. The most valuable feedback can be sourced through post-market surveillance, consumer complaints and adherence outcomes, allowing for continuous improvements to be made in packaging design and the methodologies used to test their safety.

As we have shown, creating packaging solutions which adheres to child-resistant regulations and accessibility for seniors requires a collaborative approach between a range of stakeholders and knowledge bases. This is why events like the inaugural Pharmapack Asia, [5] taking place on 3-4 November 2026 at Singapore’s Marina Bay Sands offer an ideal destination for companies across the value chain to come together and cement best practices with professionals who know the Asia-Pacific pharma market inside and out.

[1] United Nations Department of Economic and Social Affairs. World Population Ageing 2023: Asia-Pacific Regional Analysis. United Nations publication, 2023. [https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/undesa_pd_2024_wpa2023-report.pdf]

[2] World Health Organization (WHO). Adherence to Long-Term Therapies: Evidence for Action. WHO technical report, 2003. [https://iris.who.int/bitstreams/121c6b73-8651-442f-9560-e3b1d9c8a75c/download]

[3] Organisation for Economic Co-operation and Development (OECD). Health at a Glance: Asia/Pacific 2024. OECD publication, 2024. [https://www.oecd.org/content/dam/oecd/en/publications/reports/2024/11/health-at-a-glance-asia-pacific-2024_2cea11ae/51fed7e9-en.pdf]

[5] International Organization for Standardization (ISO). ISO 8317:2015 Child-Resistant Packaging — Requirements and Testing Procedures for Reclosable Packages. International standard, 2015. [https://cdn.standards.iteh.ai/samples/61650/0117cd4500034231be51797b89f152bc/ISO-8317-2015.pdf]

[6] SOCRA. Human Factors Testing and Clinical Research. Trade publication, 2020. [https://www.socra.org/blog/human-factors-testing-and-clinical-research/]

[7] Informa Markets. Pharmapack Asia 2026: Packaging Zone Programme Information. Event documentation, 2025. [https://www.pharmapackasia.com/]